920: TP-317, AN ORAL BLT1 AGONIST, ENHANCES IMMUNE CHECKPOINT INHIBITOR THERAPY BY STIMULATING TUMOR ANTIGEN PRESENTATION IN A MICROSATELLITE STABLE TUMOR MODEL OF COLORECTAL CANCER
920: TP-317, AN ORAL BLT1 AGONIST, ENHANCES IMMUNE CHECKPOINT INHIBITOR THERAPY BY STIMULATING TUMOR ANTIGEN PRESENTATION IN A MICROSATELLITE STABLE TUMOR MODEL OF COLORECTAL CANCER
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.